Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

OBJECTIVES: To establish the cost-effectiveness of dacomitinib compared to gefitinib from the Chinese healthcare system perspective. PATIENTS: Advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. METHODS: Partitioned survival analysis was undertak...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yong-feng, Luan, Luan, Zhu, Fan-fan, Dong, Peng, Ma, Li-Heng, Li, Lan-ting, Gao, Lan, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712321/
https://www.ncbi.nlm.nih.gov/pubmed/34970476
http://dx.doi.org/10.3389/fonc.2021.564234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712321/
https://www.ncbi.nlm.nih.gov/pubmed/34970476
http://dx.doi.org/10.3389/fonc.2021.564234

Ejemplares similares